The Phase 3 EPIC trial is a randomized, sham-controlled, double-blind study evaluating NRTX-1001 cell therapy in adults with ...

Supernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an ...

Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with ...

Four-year results of a phase III trial showed that budesonide oral suspension (Eohilia) for eosinophilic esophagitis was well ...

Several individuals enrolled in a phase 3 trial for Eli Lilly's (NYSE:LLY) next-generation obesity drug, retatrutide, say ...

The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...

Zealand Pharma achieved notable organizational growth in 2024 with a 30% increase in the number of employees compared to 2023 ...

X4 has entered an exclusive agreement with taiba rare for distributing and commercialising Xolremdi in select Middle Eastern ...

BridgeBio's launch of Attruby in the U.S. is off to a strong start. Read how this successful effort puts the biotech in a ...

FDA has granted priority review for Boehringer Ingelheim’s zongertinib NDA for treating unresectable or metastatic NSCLC.